Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia

Dominique Bollino, Xinrong Ma, Kayla M. Tighe, Andrea Casildo, Katharina Richard, Antonino Passaniti, Brandon Carter-Cooper, Erin T. Strovel, Ashkan Emadi · 2024

Read Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia by Dominique Bollino, Xinrong Ma, Kayla M. Tighe, Andrea Casildo, Katharina Richard, Antonino Passaniti, Brandon Carter-Cooper, Erin T. Strovel, Ashkan Emadi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11641566.txt.

Description

Dominique Bollino and co-authors test drug mixes against acute myeloid leukemia in a 2024 lab study. The cancer is a fast-growing blood disease. One drug in the mix, calaspargase pegol, is a long-acting enzyme that starves cancer cells of a food amino acid. Two partner drugs block proteins that keep cells alive, called BCL-2 and MCL-1. Blocking MCL-1 may beat a common route of drug escape.

Tests used human cancer cell lines, patient samples, and mice carrying human tumors. The enzyme drug made the BCL-2 blocker work harder against the cancer. It did not change the MCL-1 blocker's effect. The strong pair also slowed protein making inside cells. The authors back human trials of the enzyme drug with BCL-2 blocking.

Catalog record

CREATORDominique Bollino, Xinrong Ma, Kayla M. Tighe, Andrea Casildo, Katharina Richard, Antonino Passaniti, Brandon Carter-Cooper, Erin T. Strovel, Ashkan Emadi
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11641566

Browse the full library · About the Tower of Babel